Axitinib Tablets / 阿昔替尼片

Axitinib Tablets / 阿昔替尼片
Product Description

  • Largest-selling drug in the global renal cancer market – global sales reached 978 million USD in 2024, with a 5-year CAGR of 12.7%.

    • The only approved first-line targeted-immunotherapy combination in China (with toripalimab), listed as Category IA recommendation in 2024 CSCO guidelines.

    Excellent clinical efficacy – median PFS of 18 months and ORR of 58.1% when combined with toripalimab in first-line treatment.

    Shares sales channels with apalutamide in urology and oncology departments, enabling synergistic promotion.

    Read more Show less

    Biotech Pharmaceutical Co., Ltd.

    • Country/Region:
      China
    • Founded:
      2000
    • On CPHI since:
      2026
    • Certificates:
      1
    • Employees:
      1000 - 4999
    Company types
    Pharmaceutical company
    Primary activities
    Pharmaceutical Company (generic finished products)
    Pharmaceutical Company (innovator finished products)
    View company profile
    Categories
    more categories Show less
    Specifications
    • Details
      5mg
    • Selling Points
      Best selling product in renal cancer 
    • Supplied from
      China
    More specifications Fewer specifications

    Biotech Pharmaceutical Co., Ltd.

    • Country/Region:
      China
    • Founded:
      2000
    • On CPHI since:
      2026
    • Certificates:
      1
    • Employees:
      1000 - 4999
    Company types
    Pharmaceutical company
    Primary activities
    Pharmaceutical Company (generic finished products)
    Pharmaceutical Company (innovator finished products)
    View company profile

    More Products from Biotech Pharmaceutical Co., Ltd. (3)

    • Apalutamide /ˌeɪpəˈluːtəmaɪd/ Tablets / 阿帕他胺片

      Product Apalutamide /ˌeɪpəˈluːtəmaɪd/ Tablets / 阿帕他胺片

      • Large and fast-growing market – global sales reached 3.574 billion USD, with growth exceeding that of enzalutamide.

      Only the originator (Janssen) is available in China; generic entry is expected to achieve rapid volume uptake.

      Expanding patient pool – prostate cancer incidence is ...
    • Ebidetide Injection (JY09) / 益百得肽注射液

      Product Ebidetide Injection (JY09) / 益百得肽注射液

      1.Has a half-life of up to 240 hours and is the first bi-weekly GLP-1 receptor agonist globally to enter Phase III, significantly improving patient compliance.2.Precisely regulates insulin secretion only when blood glucose is elevated, resulting in an extremely low risk of hypoglycemia.3.Incidence of ...
    • Nimoutuzumab Injection

      Product Nimoutuzumab Injection

      Our flagship product, Nimotuzumab, is a humanized anti‑EGFR monoclonal antibody. Since its launch in China in 2008, it has been approved for the treatment of nasopharyngeal carcinoma, pancreatic cancer, and head and neck tumors, demonstrating robust clinical efficacy and a favorable safety profile. Annual ...